Ajooni Biotech Limited (IN:AJOONI)
:AJOONI
Want to see IN:AJOONI full AI Analyst Report?
Top Page
Ajooni Biotech Limited
(AJOONI)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹4.50
▼(-12.28% Downside)
Action:ReiteratedDate:03/03/26
The score is primarily supported by strong revenue growth and a low-leverage, high-equity balance sheet, but is held back by negative operating/free cash flow and a clear technical downtrend with weak momentum. Valuation is moderate based on the P/E ratio, providing limited offset.
Positive Factors
Strong Revenue Growth
A 43.2% year-over-year revenue increase signals durable demand expansion in cattle feed and related products. Sustained top-line growth supports capacity utilization, provides room for operating leverage, and underpins longer-term margin improvement as fixed costs are absorbed.
Negative Factors
Negative Operating and Free Cash Flow
Reported negative operating and free cash flow means earnings are not converting to cash, creating reliance on external or financing cash inflows. Over 2-6 months this constrains investment in capacity, working capital buffers, and raises liquidity vulnerability during input cost shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
A 43.2% year-over-year revenue increase signals durable demand expansion in cattle feed and related products. Sustained top-line growth supports capacity utilization, provides room for operating leverage, and underpins longer-term margin improvement as fixed costs are absorbed.
Read all positive factors
Ajooni Biotech Limited (AJOONI) vs. iShares MSCI India ETF (INDA)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)354.25K
Price to Earnings (P/E)11.3
Beta (1Y)1.00
Revenue Growth43.84%
EPS Growth35.06%
CountryIN
Employees109
SectorHealthcare
Sector Strength45
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.10
Shares Outstanding172,243,590
10 Day Avg. Volume263,831
30 Day Avg. Volume354,249
Financial Highlights & Ratios
PEG Ratio-1.89
Price to Book (P/B)1.26
Price to Sales (P/S)0.97
P/FCF Ratio-5.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ajooni Biotech Limited Business Overview & Revenue Model
Company Description
Ajooni Biotech Limited manufactures and sells animal feed in India. The company offers cattle feeds and feed supplements. Ajooni Biotech Limited was incorporated in 2010 and is based in Mohali, India....
How the Company Makes Money
Ajooni Biotech Limited primarily makes money by selling compound cattle feed and allied livestock nutrition products to customers in the dairy and livestock value chain (e.g., farmers, dairy operators, and feed distributors/retail channels). Reven...
Ajooni Biotech Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
85
Very Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.26B | 1.15B | 801.15M | 744.88M | 740.38M | 510.39M |
| Gross Profit | 216.88M | 138.13M | 97.65M | 87.45M | 100.24M | 80.26M |
| EBITDA | 56.51M | 57.57M | 44.27M | 30.60M | 31.12M | 15.77M |
| Net Income | 37.39M | 32.38M | 21.61M | 11.25M | 10.49M | 3.73M |
Balance Sheet | ||||||
| Total Assets | 1.04B | 950.51M | 475.20M | 587.31M | 290.18M | 280.26M |
| Cash, Cash Equivalents and Short-Term Investments | 152.87M | 68.30M | 4.30M | 4.93M | 573.86K | 2.44M |
| Total Debt | 88.71M | 19.40M | 21.68M | 51.77M | 53.50M | 67.84M |
| Total Liabilities | 143.18M | 69.72M | 48.12M | 170.62M | 126.35M | 123.76M |
| Stockholders Equity | 897.92M | 880.79M | 427.08M | 416.69M | 163.82M | 156.51M |
Cash Flow | ||||||
| Free Cash Flow | 18.31M | -192.16M | -95.54M | -84.39M | 15.60M | -23.71M |
| Operating Cash Flow | 135.46M | -171.84M | -39.52M | -55.79M | 36.84M | 11.56M |
| Investing Cash Flow | -122.77M | -171.34M | 76.37M | -158.24M | -18.97M | -34.10M |
| Financing Cash Flow | 71.88M | 248.26M | -35.66M | 216.55M | -19.73M | 23.74M |
Ajooni Biotech Limited Technical Analysis
Neutral
5.13
Price Trends
4.44
Negative
4.38
Negative
4.88
Negative
Market Momentum
-0.02
Negative
50.95
Neutral
60.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AJOONI, the sentiment is Neutral. The current price of 5.13 is above the 20-day moving average (MA) of 4.15, above the 50-day MA of 4.44, and above the 200-day MA of 4.88, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.95 is Neutral, neither overbought nor oversold. The STOCH value of 60.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:AJOONI.
Ajooni Biotech Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ₹1.47B | 111.96 | ― | ― | ― | ― | |
63 Neutral | ₹815.73M | 21.33 | ― | ― | 15.04% | -11.75% | |
61 Neutral | ― | 11.26 | ― | ― | 43.84% | 35.06% | |
56 Neutral | ₹548.92M | 172.45 | ― | ― | -27.51% | 356.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹398.81M | -4.63 | ― | ― | -48.93% | -180.45% |
* Healthcare Sector Average
IN:AJOONI
Ajooni Biotech Limited
4.20
-1.74
-29.29%
IN:BALAXI
Balaxi Pharmaceuticals Limited
26.63
-28.00
-51.25%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
33.73
-10.54
-23.81%
IN:LASA
Lasa Supergenerics Ltd.
7.96
-9.06
-53.23%
IN:VAISHALI
Vaishali Pharma Ltd.
7.61
-4.80
-38.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.